What is he best known for?
The fields of study he is best known for:
- Cancer
- Chemotherapy
- Internal medicine
Bonnie S. Glisson mainly focuses on Internal medicine, Surgery, Chemotherapy, Radiation therapy and Oncology.
His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology.
His Chemotherapy research incorporates themes from Liver function, Squamous carcinoma and Epidermoid carcinoma.
His biological study spans a wide range of topics, including Salvage therapy and Laryngectomy.
His work in Oncology addresses issues such as Clinical trial, which are connected to fields such as Toxicity and Salivary gland.
His studies in Cisplatin integrate themes in fields like Cancer research, Urology, Tolerability, Fluorouracil and Larynx.
His most cited work include:
- Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer (2294 citations)
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (931 citations)
- Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer (694 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Chemotherapy, Lung cancer and Cancer research.
In his study, Toxicity is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine.
The concepts of his Oncology study are interwoven with issues in Head and neck squamous-cell carcinoma and Epidermal growth factor receptor.
Chemotherapy is the subject of his research, which falls under Surgery.
His research in Surgery intersects with topics in Carcinoma and Epidermoid carcinoma.
His Lung cancer research includes themes of Gemcitabine and Adenocarcinoma.
He most often published in these fields:
- Internal medicine (56.42%)
- Oncology (46.87%)
- Chemotherapy (26.27%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (56.42%)
- Oncology (46.87%)
- Cancer research (23.28%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Cancer research, Lung cancer and Cancer.
The Oncology study combines topics in areas such as Head and neck squamous-cell carcinoma, Radiation therapy and Chemotherapy, Phases of clinical research.
His Radiation therapy study combines topics in areas such as Survival analysis, Performance status and Head and neck.
His work deals with themes such as Immune checkpoint, Blockade, Immunotherapy, Cell and Non small cell, which intersect with Cancer research.
His Lung cancer study integrates concerns from other disciplines, such as Survival rate and Reverse phase protein lysate microarray.
His research on Cancer frequently connects to adjacent areas such as Cohort.
Between 2017 and 2021, his most popular works were:
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer (183 citations)
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. (137 citations)
- Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. (120 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Cancer.
His study in Induction chemotherapy, Phases of clinical research, Radiation therapy, Nivolumab and Chemotherapy is carried out as part of his Internal medicine studies.
His research integrates issues of Regimen, Immune checkpoint inhibitors, PD-L1, Targeted therapy and Clinical endpoint in his study of Oncology.
His Lung cancer research integrates issues from Survival rate, Rovalpituzumab tesirine and Carcinoma.
His study in Cancer research is interdisciplinary in nature, drawing from both Immune checkpoint, Immunotherapy, Gene expression, Allele frequency and DNA repair.
His studies deal with areas such as Basal cell carcinoma, Eyelid Carcinoma and Surgery as well as Cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
